scholarly journals 327 Advanced ovarian cancer survival rates in a mediterranean population: an 8-year real-world national analysis of the Maltese Islands

2021 ◽  
Author(s):  
V Cassar ◽  
MC Tabone ◽  
MP Agius ◽  
Y Muscat Baron
Keyword(s):  
Ovarian Cancer ◽  
Real World ◽  
Cancer Survival ◽  
Survival Rates ◽  
Advanced Ovarian Cancer ◽  
Mediterranean Population ◽  
Maltese Islands ◽  
Ovarian Cancer Survival ◽  
National Analysis

Vaginal hysterectomy with or without bilateral salpingo-oophorectomy may be an alternative treatment for endometrial cancer patients with medical co-morbidities precluding standard surgical procedures: a systematic review

2019 ◽  
Vol 29 (2) ◽  
pp. 299-304 ◽  
Author(s):  
Arnold-Jan Kruse ◽  
Henk G ter Brugge ◽  
Harm H de Haan ◽  
Hugo W Van Eyndhoven ◽  
Hans W Nijman
Keyword(s):  
Ovarian Cancer ◽  
Endometrial Cancer ◽  
Vaginal Hysterectomy ◽  
Cancer Survival ◽  
Survival Rates ◽  
Survival Outcomes ◽  
Ovarian Malignancy ◽  
Post Menopausal ◽  
Ovarian Cancer Survival ◽  
Overall Survival Rates

ObjectiveVaginal hysterectomy with bilateral salpingo-oophorectomy may be an alternative strategy for patients with low-risk endometrial cancer and medical co-morbidities precluding laparoscopic or abdominal procedures. The current study evaluates the prevalence of co-existent ovarian malignancy in patients with endometrial cancer and the influence of bilateral salpingo-oophorectomy on survival outcomes in these patients.MethodsMedline and EMBASE were searched for studies published between January 1, 2000 and November 20, 2017 that investigated (1) the prevalence of co-existing ovarian malignancy (either metastases or primary synchronous ovarian cancer in women with endometrial cancer, and (2) the influence of bilateral salpingo-oophorectomy on recurrence and/or survival rates.ResultsOf the pre-menopausal and post-menopausal patients (n=6059), 373 were identified with metastases and 106 were identified with primary synchronous ovarian cancer. Of the post-menopausal patients (n=6016), 362 were identified with metastases and 44 were identified with primary synchronous ovarian cancer. Survival outcomes did not differ for pre-menopausal patients with endometrial cancer with and without bilateral salpingo-oophorectomy (5-year overall survival rates were 89–94.5% and 86–97.8%, respectively).ConclusionBilateral salpingo-oophorectomy during vaginal hysterectomy seems to have a limited impact on disease outcome in patients with endometrial cancer. These results support the view that vaginal hysterectomy alone or with bilateral salpingo-oophorectomy may be an option for patients with endometrial cancer who are not ideal surgical candidates.

scholarly journals Sociodemographic Disparities in Advanced Ovarian Cancer Survival and Adherence to Treatment Guidelines

2015 ◽  
Vol 125 (4) ◽  
pp. 833-842 ◽  
Author(s):  
Robert E. Bristow ◽  
Jenny Chang ◽  
Argyrios Ziogas ◽  
Belinda Campos ◽  
Leo R. Chavez ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Survival ◽  
Treatment Guidelines ◽  
Advanced Ovarian Cancer ◽  
Adherence To Treatment ◽  
Sociodemographic Disparities ◽  
Ovarian Cancer Survival

scholarly journals Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin

2019 ◽  
Vol 10 (4) ◽  
pp. 55
Author(s):  
Aneta Cymbaluk-Płoska ◽  
Peter Sobolewski ◽  
Anita Chudecka-Głaz ◽  
Ewa Wiśniewska ◽  
Joanna Łapczuk ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Survival ◽  
Survival Rates ◽  
Double Emulsion ◽  
Ovarian Adenocarcinoma ◽  
Local Inflammatory Response ◽  
Sustained Drug Delivery ◽  
Emulsion Process ◽  
Ovarian Cancer Survival

Despite on-going medical advances, ovarian cancer survival rates have stagnated. In order to improve IP delivery of platinum-based antineoplastics, we aimed to develop a sustained drug delivery system for carboplatin (CPt). Toward this aim, we pursued a double emulsion process for obtaining CPt-loaded microcapsules composed of poly(ethylene terephthalate-ethylene dilinoleate) (PET-DLA) copolymer. We were able to obtain PET-DLA microspheres in the targeted size range of 10–25 µm (median: 18.5 µm), to reduce intraperitoneal clearance by phagocytosis and lymphoid transit. Empty microspheres showed the lack of toxicity in vitro. The double emulsion process yielded 2.5% w/w CPt loading and obtained microcapsules exhibited sustained (>20 day) zero-order release. The encapsulated CPt was confirmed to be bioavailable, as the microcapsules demonstrated efficacy against human ovarian adenocarcinoma (SK-OV-3) cells in vitro. Following intraperitoneal injection in mice, we did not observe adhesions, only mild, clinically-insignificant, local inflammatory response. Tissue platinum levels, monitored over 14 days using atomic absorption spectroscopy, revealed low burst and reduced systemic uptake (plasma, kidney), as compared to neat carboplatin injection. Overall, the results demonstrate the potential of the developed microencapsulation system for long-term intraperitoneal sustained release of carboplatin for the treatment of ovarian cancer.

scholarly journals Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin

2019 ◽  
Author(s):  
Aneta Cymbaluk-Płoska ◽  
Peter Sobolewski ◽  
Anita Chudecka-Głaz ◽  
Ewa Wiśniewska ◽  
Joanna Łapczuk ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Survival ◽  
Survival Rates ◽  
Double Emulsion ◽  
Ovarian Adenocarcinoma ◽  
Local Inflammatory Response ◽  
Sustained Drug Delivery ◽  
Emulsion Process ◽  
Ovarian Cancer Survival

<p>Despite on-going medical advances, ovarian cancer survival rates have stagnated. In order to improve IP delivery of platinum-based antineoplastics, we aimed to develop a sustained drug delivery system for carboplatin (CPt). Toward this aim, we pursued a double emulsion process for obtaining CPt-loaded microcapsules composed of poly(ethylene terephthalate-ethylene dilinoleate) (PET‑DLA) copolymer. We were able to obtain PET-DLA microspheres in the targeted size range of 10–25 µm (median: 18.5 µm), to reduce intraperitoneal clearance by phagocytosis and lymphoid transit. Empty microspheres showed the lack of toxicity <i>in vitro</i>. The double emulsion process yielded 2.5% w/w CPt loading and obtained microcapsules exhibited sustained (>20 day) zero-order release. The encapsulated CPt was confirmed to be bioavailable, as the microcapsules demonstrated efficacy against human ovarian adenocarcinoma (SK-OV-3) cells <i>in vitro. </i>Following intraperitoneal injection in mice, we did not observe adhesions, only mild clinically-insignificant, local inflammatory response. Tissue platinum levels, monitored over 14 days using atomic absorption spectroscopy, revealed low burst and reduced systemic uptake (plasma, kidney), as compared to neat carboplatin injection. Overall, the results demonstrate the potential of the developed microencapsulation system for long-term intraperitoneal sustained release of carboplatin for</p><div><div><div><p>the treatment of ovarian cancer.</p></div></div></div>

EP997 Treatment tailoring in epithelial advanced ovarian cancer: survival results in navarre

2019 ◽  
Author(s):  
CM Tauste Rubio ◽  
J Zabaleta Jurío ◽  
S Aguirre Gorospe ◽  
J Barrenetxea Arrinda ◽  
B Gaston Moreno ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Survival ◽  
Advanced Ovarian Cancer ◽  
Ovarian Cancer Survival

scholarly journals Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin

2019 ◽  
Author(s):  
Aneta Cymbaluk-Płoska ◽  
Peter Sobolewski ◽  
Anita Chudecka-Głaz ◽  
Ewa Wiśniewska ◽  
Joanna Łapczuk ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Survival ◽  
Survival Rates ◽  
Double Emulsion ◽  
Ovarian Adenocarcinoma ◽  
Local Inflammatory Response ◽  
Sustained Drug Delivery ◽  
Emulsion Process ◽  
Ovarian Cancer Survival

<div><div><div><p>Despite on-going medical advances, ovarian cancer survival rates have stagnated. In order to improve IP delivery of platinum-based antineoplastics, we aimed to develop a sustained drug delivery system for carboplatin (CPt). Toward this aim, we pursued a double emulsion process for obtaining CPt-loaded microcapsules composed of poly(ethylene terephthalate-ethylene dilinoleate) (PET‑DLA) copolymer. We were able to obtain PET-DLA microspheres in the targeted size range of 10–25 µm (median: 18.5 µm), to reduce intraperitoneal clearance by phagocytosis and lymphoid transit. Empty microspheres showed the lack of toxicity <i>in vitro</i>. The double emulsion process yielded 2.5% w/w CPt loading and obtained microcapsules exhibited sustained (>20 day) zero-order release. The encapsulated CPt was confirmed to be bioavailable, as the microcapsules demonstrated efficacy against human ovarian adenocarcinoma (SK-OV-3) cells <i>in vitro. </i>Following intraperitoneal injection in mice, we did not observe adhesions, only mild clinically-insignificant, local inflammatory response. Tissue platinum levels, monitored over 14 days using atomic absorption spectroscopy, revealed low burst and reduced systemic uptake (plasma, kidney), as compared to neat carboplatin injection. We conclude that the developed microencapsulation system could be used for long-term intraperitoneal sustained release of carboplatin for the treatment of ovarian cancer. </p></div></div></div>

scholarly journals Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin

2019 ◽  
Author(s):  
Aneta Cymbaluk-Płoska ◽  
Peter Sobolewski ◽  
Anita Chudecka-Głaz ◽  
Ewa Wiśniewska ◽  
Joanna Łapczuk ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Survival ◽  
Survival Rates ◽  
Double Emulsion ◽  
Ovarian Adenocarcinoma ◽  
Local Inflammatory Response ◽  
Sustained Drug Delivery ◽  
Emulsion Process ◽  
Ovarian Cancer Survival

<p>Despite on-going medical advances, ovarian cancer survival rates have stagnated. In order to improve IP delivery of platinum-based antineoplastics, we aimed to develop a sustained drug delivery system for carboplatin (CPt). Toward this aim, we pursued a double emulsion process for obtaining CPt-loaded microcapsules composed of poly(ethylene terephthalate-ethylene dilinoleate) (PET‑DLA) copolymer. We were able to obtain PET-DLA microspheres in the targeted size range of 10–25 µm (median: 18.5 µm), to reduce intraperitoneal clearance by phagocytosis and lymphoid transit. Empty microspheres showed the lack of toxicity <i>in vitro</i>. The double emulsion process yielded 2.5% w/w CPt loading and obtained microcapsules exhibited sustained (>20 day) zero-order release. The encapsulated CPt was confirmed to be bioavailable, as the microcapsules demonstrated efficacy against human ovarian adenocarcinoma (SK-OV-3) cells <i>in vitro. </i>Following intraperitoneal injection in mice, we did not observe adhesions, only mild clinically-insignificant, local inflammatory response. Tissue platinum levels, monitored over 14 days using atomic absorption spectroscopy, revealed low burst and reduced systemic uptake (plasma, kidney), as compared to neat carboplatin injection. Overall, the results demonstrate the potential of the developed microencapsulation system for long-term intraperitoneal sustained release of carboplatin for</p><div><div><div><p>the treatment of ovarian cancer.</p></div></div></div>

Ambient air pollution and ovarian cancer survival in California

2021 ◽  
Author(s):  
Carolina Villanueva ◽  
Jenny Chang ◽  
Argyrios Ziogas ◽  
Robert E. Bristow ◽  
Verónica M. Vieira
Keyword(s):  
Ovarian Cancer ◽  
Air Pollution ◽  
Cancer Survival ◽  
Ambient Air ◽  
Ambient Air Pollution ◽  
Ovarian Cancer Survival
Sign in / Sign up

Export Citation Format

Share Document